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ABSTRACT
Hepatitis C, caused by the hepatitis C virus (HCV), is a major public health issue in Russia. The aim of
our study was to assess the seroprevalence of markers of HCV exposure and factors associated with
HCV seropositivity among the general population aged 18–39 years in the city of Arkhangelsk,
Northwest Russia. A social research agency applied a quota sampling method to recruit study
participants using cell phone numbers. All participants (n = 1243) completed a self-administered
questionnaire and provided a blood sample. Sixty-five participants (5.2%, 95% confidence interval [CI]
4.9–5.5) tested positive for HCV IgM+G antibodies, and of these, 55 (84.6%) did not know that they
were exposed to HCV. Inmultivariable logistic regression analysis, HCV seropositivity was significantly
associated with older age, a history of injecting drug use, and having ever received a blood transfu-
sion. To reach the goal of the World Health Organisation’s Global Health Sector Strategy on Viral
Hepatitis, regional preventive programmes should include measures to reduce injecting drug use as
well as scaling up harm-reduction and treatment programs for drug addicts.
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The prevalence of hepatitis C virus (HCV) infection is high
worldwide [1]. HCV is a blood-borne virus which can be
transmitted through injecting drug use (IDU), transfusion of
infected blood, and reuse or inadequate sterilisation of
medical equipment. It can also be transmitted frommother
to child and in rare cases during unprotected sex [2]. HCV
can cause acute hepatitis, but about 80% of the infected
people do not develop symptoms [3]. From 60% to 80% of
HCV-infected persons develop chronic hepatitis C, which
can be asymptomatic for decades, butmay lead to cirrhosis
or hepatocellular carcinoma [4]. Globally, more than
71 million people have chronic HCV infection, and about
400,000 people die annually due to HCV infection [3].
Worldwide, the countries with the highest number of HCV
cases are China, Pakistan, India, Egypt and Russia [5]. At
present, there is no vaccine against HCV [3]. Although new
antiviral medicines can cure more than 95% of HCV-
infected people, access to diagnostic procedures and treat-
ment is still low on the global scale [6].
In 2016, the World Health Assembly adopted the first
Global Health Sector Strategy on Viral Hepatitis, with the
global aim of reducing the incidence of HCV infection by
90% and mortality due to HCV infection by 65% by 2030.
The World Health Organisation (WHO) proposed 10 core
indicators to support the implementation andmonitoring
of the strategy [7]. The WHO Regional office for Europe
assessed the availability of the data for each core indicator
in the region and came to the conclusion that current
data sources in most European countries are insufficient
and that seroprevalence surveys are required to deter-
mine the size of the undiagnosed population [8].
HCV infection is an important public health issue in
Russia [9]. In 2018, the incidence of reported acute
hepatitis C was 1.1 per 100,000 while the incidence of
reported chronic hepatitis C was 32.7 per 100,000
(Figure 1) [10]. About 60% of chronic hepatitis C cases
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are diagnosed among adults aged 20–39 years [11].
Russia has a national strategy for preventing HCV infec-
tion. All Russian citizens have the right to treatment for
HCV infection free of charge. Moreover, HCV testing is
free of charge for blood donors, pregnant women, and
recipients of blood transfusions. HCV testing is obliga-
tory for health-care workers and patients who are con-
sidered to be at increased risk for viral hepatitis [12].
People who inject drugs are eligible for free of charge
treatment in public health-care facilities. The total eco-
nomic burden of hepatitis C in Russia was estimated to
be 48 billion Russian rubles (~0.83 billion US dollars) in
2010 and continues to increase [13].
The only study on the seroprevalence of HCV in Russia
conducted the last 20 years was published in Russian, and
is unavailable to the international audience [14]. This
study was conducted in 2008 in five Russian regions
(Moscow, Rostov, and Sverdlovsk Regions, as well as the
Tyva and Sakha (Yakutia) Republics). All these settings are
situated thousands of kilometres away from the
Arkhangelsk Region where our study was performed.
The overall seroprevalence of HCV among the participants
of all ages in the study was 2.6% [14].
The aim of our study was to assess the seroprevalence
of markers of HCV exposure and factors associated with
HCV seropositivity among adults aged 18–39 years in the
city of Arkhangelsk, Northwest Russia. Further, to deter-
mine the proportion of that population with undiagnosed
HCV infection, thus providing key information to health
authorities needed to scale up interventions proposed by
theWHO’s Global Health Sector Strategy on Viral Hepatitis
in this part of Russia [8].
Materials and methods
Study population and study design
This study was a part of a large Russian-Norwegian project
[15], and it drew its study sample from the general popula-
tion aged 18–39 in the Arctic Russian city of Arkhangelsk
using a quota sampling method [16]. Arkhangelsk has
a population of approximately 350,000 people, and the
official data show that its population has an incidence of
acute (1.48 per 100,000 in 2018) and chronic (40.8 per
100,000 in 2018) hepatitis C that is close to the national
average. A social research agency recruited participants
using cell phone numbers. All participants completed
a self-administered questionnaire and provided a blood
sample between September 2010 and June 2011.
Detailed information on enrolment procedures, question-
naire data, and sample collection has been described else-
where [15]. Altogether, 1265 adults participated in the
study. Twenty-two of them had missing blood test results
and were excluded from the analyses. Thus, the final study
sample consisted of 1243 participants.
Description of the variables
The participants provided information on demographic
factors, socioeconomic factors, smoking status, alcohol
use, sexual and preventive behaviour, history of sexually
transmitted infections (STIs)/HIV, injecting drug use (IDU),
blood donation, blood transfusions, operations, tattoos,
and whether they knew anyone with hepatitis
C. Participants reported their family income on a scale of 1
to 10, based on how they thought their income compared
Figure 1. Incidence of hepatitis C (HC) in Russia and the Arkhangelsk region in 1996–2018 (per 100,000 population).
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to the average income in Arkhangelsk.We then categorised
these responses as low (1–4), medium (5–7), and high
(8–10) income. Having tattoos was dichotomised as “yes”
and “no”. The variable “knowing someone with hepatitis C”
was divided into “no”, “yes”, and “do not know”. The
description of other variables used in this study can be
found elsewhere [17].
Serological testing and reporting of test results
Serum samples were sent daily to the research labora-
tory of the Northern State Medical University (NSMU),
where they were centrifuged and frozen at −20°C. Once
a month, all untested samples were transported to the
laboratory of the Regional STI clinic in Arkhangelsk,
where serological tests for HCV IgM+G, were done by
enzyme-linked immunosorbent assay, according to the
manufacturer’s instructions. A confirmation test was
performed in case of positive results on IgM+G. The
sample was tested for antibodies to HCV antigens cor-
responding to the parts of proteins encoded by the
structural (core) and non-structural (NS3, NS4, NS5)
genome parts. If a participant had positive results for
one or both tests (IgM+G or IgM), he/she was consid-
ered to have been exposed to HCV and was categorised
as seropositive. All reagents were produced by the
Vector-Best company, Novosibirsk, Russia.
All participants were asked to provide a contact
e-mail address or telephone number so they could be
informed on their test results and the results were
reported via e-mail or cell phones. The participants
with positive test results were referred to a specialist
in infectious diseases who reported back that 17 of
them complied. Further follow-up and RNA testing of
positive participants was not part of this study as
these participants were referred to the health service.
Statistical analyses
The direct standardisation technique was applied to
provide the age-standardised seroprevalence of mar-
kers of HCV infection to the 2010 Arkhangelsk popula-
tion, based on the 2010 census. Associations between
HCV seropositivity and independent variables were stu-
died using crude logistic regression. All associations
with p < 0.15 or lower in crude analyses were included
in the multivariable model [18]. Crude and adjusted
odds ratios with 95% confidence intervals (CIs) were
estimated. All analyses were performed using
Statistical Package for Social Sciences version 20 (SPSS,
Inc., Chicago, IL, USA).
Ethical approval
This study was conducted in accordance with the
Helsinki Declaration and approved by the Ethical
Committee at the NSMU in the city of Arkhangelsk
(Protocol 04/03 from 15 March 2010). The participants
were given an invitation letter with information about
the study aims, procedures, and a telephone number
they could call to obtain their test results. All partici-
pants signed a written informed consent form.
Results
The final study sample consisted of 543 men and 700
women (mean age 27.6, standard deviation [SD] = 5.6
years and 27.0, SD = 5.7 years, respectively). Most of the
participants had high education (58.9%) and medium
income (72.0%). Ever smokers comprised 60.5% of the
study sample, and 80.5% of participants reported at
least one episode of binge drinking (at least 6 units of
alcohol in one occasion) (Table 1). Previous HIV testing
was reported by 55.4% of men and 73.9% of women. No
one reported being diagnosed with HIV infection (data
not shown). A history of IDUwas reported by 2.7% (n = 34)
of the sample, and of those, 14 were seropositive (10 men
and 4 women). More than one-fifth of the sample had
ever donated blood; 4.7% had ever received a blood
transfusion. Among the participants, 12.1% knew some-
one with hepatitis C, and 16.9% did not know if they knew
someone with hepatitis C (Table 1).
Laboratory results revealed that 65 participants
(5.2%, 95% CI 4.9–5.5) tested positive for HCV IgM+G
antibodies, among whom six tested positive for IgM,
only. The seroprevalence of markers of HCV exposure
was 6.4% (95% CI 4.5–8.9) among men and 4.3% (95%
CI 2.9–6.1) among women. Fifty-five of the 65 seropo-
sitive participants (84.6%) did not know that they were
exposed to HCV; eight (12.3% of seropositive partici-
pants) had been previously told by medical workers
that they had HCV infection, and two persons (3.1%)
did not know whether or not they had ever had HCV
infection.
Compared to the group-level census data from
Arkhangelsk in the same period, women and younger indi-
viduals were slightly overrepresented in our study sample.
After direct standardisation by age, the overall seropreva-
lence ofmarkers of HCVexposure increased to 5.6% (95%CI
5.3–5.9). It increased to 7.1% (95% CI 6.7–7.5) among men,
but decreased to 4.2% (95% CI 3.8–4.6) among women
(Table 1). So, the sex difference in HCV seropositivity
became significant after direct age standardisation.
In crude logistic regression, HCV seropositivity was
significantly associated with older age, age at sexual
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Table 1. Crude odds ratios (OR) and 95% confidence intervals (CI) for the association between seroprevalence of markers of
hepatitis C virus (HCV) exposure and its correlates among 1243 participants aged 18–39 years, 2010–2011, Arkhangelsk, Russia.
Variable N (%) N seropositive for HCV (%) Crude OR (95% СI)
Sex
Men 543 (43.7%) 35 (6.4%) referent
Women 700 (56.3%) 30 (4.3%) 0.65 (0.39–1.07)
Age
18–24 years 497 (40%) 18 (3.6%) referent
25–29 years 296 (23.8%) 12 (4.1%) 1.12 (0.53–2.37)
30–34 years 278 (22.4%) 20 (7.2%) 2.06 (1.07–3.97)
35–39 years 172 (13.8%) 15 (8.7%) 2.54 (1.25–5.16)
Marital status
Single 571 (45.9%) 28 (4.9%) referent
Divorced/widowed 86 (6.9%) 7 (8.1%) 1.72 (0.73–4.07)
Cohabiting 213 (17.1%) 11 (5.2%) 1.06 (0.52–2.16)
Married 373 (30.0%) 19 (5.1%) 1.04 (0.57–1.89)
Education
Low (secondary school or less) 209 (16.8%) 13 (6.2%) referent
Average (secondary/vocational) 302 (24.3%) 16 (5.3%) 0.84 (0.40–1.79)
High (incomplete higher/higher) 732 (58.9%) 36 (4.9%) 0.78 (0.41–1.50)
Income
Low 207 (16.7%) 7 (3.4%) referent
Medium 895 (72.0%) 52 (5.8%) 1.76 (0.79–3.94)
High 141 (11.3%) 6 (4.3%) 1.27 (0.42–3.86)
Smoking status
Never 491 (39.5%) 21 (4.3%) referent
Ever 752 (60.5%) 44 (5.9%) 1.39 (0.82–2.37)
Binge drinking
Never 242 (19.5%) 12 (5.0%) referent
Ever 1001 (80.5%) 53 (5.3%) 1.07 (0.56–2.04)
Age at sexual debut
≥18 years 517 (41.6%) 16 (3.1%) referent
<18 years 726 (58.4%) 49 (6.7%) 2.27 (1.27–4.03)
N of sexual partners in the last 6 months
0 and 1 941 (75.7%) 42 (4.5%) referent
≥2 302 (24.3%) 23 (7.6%) 1.77 (1.04–2.99)
Lifetime N of sexual partners
0 and 1 134 (10.8%) 5 (3.7%) referent
2–5 424 (34.1%) 11 (2.6%) 0.69 (0.23–2.01)
6 and more 685 (55.1%) 49 (7.2%) 1.99 (0.78–5.09)
Condom use during last sexual encounter
Yes 339 (27.3%) 23 (6.8%) referent
No and don’t remember 904 (72.7%) 42 (4.6%) 0.67 (0.40–1.13)
Condom use with causal partner
Always, without causal partners 1112 (89.5%) 57 (5.1%) referent
Sometimes, rare, never 131 (10.5%) 8 (6.1%) 1.20 (0.56–2.58)
Sexual relations with a partner of the same sex
Never 1197 (96.3%) 61 (5.1%) referent
Ever 46 (3.7%) 4 (8.7%) 1.77 (0.62–5.11)
Sexual relations with a person reporting injecting drug use
No 1094 (88.0%) 47 (4.3%) referent
Yes 45 (3.6%) 8 (17.8%) 4.82 (2.13–10.92)
Don’t know 104 (8.4%) 10 (9.6%) 2.37 (1.16–4.84)
History of STI (without HSV-2)
Never§§ 996 (80.1%) 49 (4.9%) referent
Yes 247 (19.9%) 16 (6.5%) 1.34 (0.75–2.40)
Injecting drug use
Never 1209 (97.3%) 51 (4.2%) referent
Ever§ 34 (2.7%) 14 (41.2%) 15.89 (7.60–33.26)
Donated blood
Never 950 (76.4%) 53 (5.6%) referent
Ever 293 (23.6%) 12 (4.1%) 0.72 (0.38–1.37)
Received a blood transfusion
Never 1184 (95.3%) 57 (4.8%) referent
Ever 59 (4.7%) 8 (13.6%) 3.10 (1.41–6.84)
Operations
Never 739 (59.5%) 34 (4.6%) referent
Ever 504 (40.5%) 31 (6.2%) 1.36 (0.82–2.24)
Tattoo
No 1071 (86.2%) 49 (4.6%) referent
Yes 172 (13.8%) 16 (9.3%) 2.14 (1.19–3.86)
Knowing someone with hepatitis C
No 883 (71.0%) 36 (4.1%) referent
Yes 150 (12.1%) 16 (10.7%) 2.81 (1.52–5.20)
Don’t know 210 (16.9%) 13 (6.2%) 1.55 (0.81–2.98)
STI: sexually transmitted infections; HSV-2: herpes simplex virus type 2
§Included 11 who didn’t want to answer
§§Included 9 who didn’t want to answer
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debut <18 years, having two or more sexual partners in
the last 6 months, having ever received a blood transfu-
sion, having a tattoo, and knowing someone with hepati-
tis C (Table 1). The highest seroprevalence of markers of
HCV infection and the strongest association with HCV
seropositivity were found among participants with
a history of IDU and those with sexual partners who had
a history of IDU. In total, 45 persons reported having had
a sexual partner with a history of IDU, 10 (22%) of whom
had a history of IDU themselves. One hundred four parti-
cipants reported that they did not know the HCV serosta-
tus of their partners. Marital status, education, income,
smoking status, binge drinking, self-reported STIs, and
ever having donated blood were not associated with
HCV seropositivity. Women had lower odds of being ser-
opositive for HCV than men. In the multivariable logistic
regression analysis, HCV seropositivity was significantly
associated with older age, history of IDU and history of
blood transfusions (Table 2).
Discussion
The seroprevalence of markers of HCV infection among
adults aged 18–39 years in the general population in
this study was 5.2%. This is twice as high as the ser-
oprevalence observed in Eastern Europe for the general
adult population (3.2% in Romania, 2.4% in Latvia, and
2.0% in Slovakia). These countries did not experience
economic collapse to the same degree as Russia with
a dramatic increase in IDU and cuts in health-care
expenditures. At the same time, a seroprevalence of
HCV of 5.9% has been reported in Italy which is similar
to our findings. Considerable variations in the preva-
lence of HCV across Europe can be explained by differ-
ent transmission routes, risk factors and prevention
strategies used in different countries [19].
Our data are in a disagreement with data on the ser-
oprevalence of markers of HCV infection among pregnant
women in the Arkhangelsk region (0.6% in 2012) [20]. We
propose two explanations for this. First, according to the
official statistics the incidence of HCV infection is higher in
the city of Arkhangelsk than in the rural areas and small
towns in the region [10]. Second, data from Europe sug-
gest that pregnant women are not a reliable population
to use when trying to estimate the seroprevalence HCV in
the general population. Indeed, a systematic review from
2017 reported that the seroprevalence of HCV among
pregnant women was several times lower than that in
the general population in European countries [19]. Data
from our study are close to data from another Russian
study published in 2001, which reported a seroprevalence
of markers HCV infection of 5.3% among adults aged
25–64 years in Siberia [21]. However, our 30–39-year-old
participants had a higher seroprevalence of markers of
HCV exposure compared to those aged 20–29 years in
Siberia (7.8% versus 3.8%). Data from another Russian
study showed a seroprevalence of HCV of 3.1% among
20–29 year-olds and 4.9% in 30–39 year-olds [14]. This
pattern may be explained by the high incidence of acute
hepatitis C among 15–29 year-olds in 1997–2002 [10]. Our
participants were aged 30–39 years in 2010–2011, thus
they were 15–29 old in 1997–2002, when the incidence of
HCV infection was high due to the IDU epidemic in the
country [9]. The highest prevalence of HCV infection have
been reported from Central Asia (3.6%) and Eastern
Europe (3.3%) followed by Central Sub-Saharan Africa
(2.1%) and North Africa/Middle East (1.7%). The preva-
lence of HCV in Central- and Western Europe, North- and
Latin America does not exceed 1% [5].
Globally, the prevalence of anti-HCV antibody is
greater amongmen, but the findings vary between coun-
tries. A study among blood donors in China did not find
gender differences in the prevalence of anti-HCV anti-
body [22]. However, the prevalence of HCV infection
among men was about twice as high as among women
in the USA and Iran [23–25]. In our study, the prevalence
of anti-HCV antibody was higher among men compared
Table 2. Hepatitis C virus (HCV) seropositivity and correlates by
multivariable logistic regression analysis among 1243 persons
in a population-based seroepidemiological study of adults aged
18–39 years, 2010–2011, Arkhangelsk (Russia).
Variable Adjusted OR 95% CI
Age
18–24 years Referent
25–29 years 0.87 0.38–2.03
30–34 years 1.80 0.88–3.68
35–39 years 2.55 1.18–5.50
Age at sexual debut
≥18 years Referent
≤17 years 1.72 0.91–3.25
N of sexual partners in the last 6
months
0 and 1 Referent
≥2 1.66 0.93–2.97
Sexual relations with a person
reporting injecting drug use
No Referent
Yes 2.22 0.80–6.13














Don’t know 1.50 0.75–3.02
OR: odds ratio, CI: confidence interval
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to women (6.4% vs. 4.3%). This may partly be explained
by more IDU among men than among women. Different
susceptibilities to the infection, different biological
responses on HCV infection in men and women as well
as social and behavioural factors were proposed to
explain gender differences [26]. The dominant rote of
transmission in the community can also partly explain
existing gender differences. Further investigation of fac-
tors explaining gender differences in the seroprevalence
of HCV markers may contribute to the development of
gender-specific preventive strategies.
In our study, a history of IDU showed the strongest
association with HCV seropositivity. This is in line with
the findings from the USA and Western Europe. People
with a recent history of IDU comprise 8.5% of all HCV
infections globally with the greatest proportions in
North America (30.5%), Latin America (22.0%) and
Eastern Europe (17.9%). The prevalence of HCV infec-
tion among people with a recent history of IDU is 39.2%
globally being the highest in Eastern Europe (48.6%),
the Caribbean (47.6%) and Latin America (46.4%).
Proportion of people with a recent history of IDU
among the total population with HCV infection is the
highest in North America (30.5%), Latin America
(22.0%), Western- (17.9%) and Eastern (17.2%) Europe
[27]. In our study, people who reported a history of ever
IDU had a HCV seroprevalence of 41.2%. Several studies
have shown a seroprevalence of markers of HCV
infection up to 80% among individuals with a history
of IDU in Russia [28–31]. According to the official data,
IDU was responsible for 40% of acute hepatitis C cases
in 1997 and for 21.5% of all new cases of acute hepatitis
C in 2010 in Russia [32]. In the Arkhangelsk Region,
41.7% (5 out of 12) of registered acute hepatitis
C cases were attributed to IDU in 2010 [20].
Drug possession is a crime in Russia; therefore some
HCV-infected participants could provide false negative
answers on their history of IDU leading to an under-
estimation of this route of transmission and potentially
biasing our associations toward the null. There is no
national programme to promote safe IDU in Russia, and
despite the effectiveness of opioid substitution therapy
and syringe exchange programmes in some countries
[33,34], such programmes are neither implemented in
the Arkhangelsk region nor in Russia in general. The
number of beds in rehabilitation facilities for people
with substance abuse disorders has increased in the
last decade; however, there is still a lack of specialists
in the field of addiction as well as equipment and
facilities for preventive and harm-reduction pro-
grammes in the region [35].
From2001 all donated blood has been screened for HCV
as a part of the national infection control policy for blood
banks [36]. In our analyses, participants with self-reported
blood transfusions had a higher risk of HCV seropositivity.
According to Order 193 07.05.2003, “About implementa-
tion of quarantine of fresh frozen plasma in practice of
work of blood service in the Russian Federation”, all blood
fromdonors had to be quarantined for 6months and could
only be used after the donor was tested for a second time.
Obviously, it took time to reorganise the blood donation
programme. We did not ask our participants to give infor-
mation on when they received blood transfusions. Unsafe
medical procedures have been reported as the most com-
mon risk factor for HCV infection in India and China [37,38].
Having a blood transfusion before 1991 is the secondmost
common risk factor for HCV infection in Europe [39]. In the
USA, the risk of HCV infection after blood transfusion
decreased from 33% in the 1960s to 0.3% in the mid-
1990s after the universal screening of blood and donors
was implemented [40].
The proportion of cases of acute Hepatitis C attributed
to medical procedures decreased from 12.8% in 1997 to
2.8 in 2010 in Russia. The corresponding numbers for
Northwest Russia were 24.4% and 2.1% ([32], Figure 1).
Taking into account that approximately 25% of people
naturally clear the infection and 75% remain chronically
infected after the exposure to HCV [41] the estimates for
the prevalence of chronic HCV infection among our parti-
cipants would be 5.3% (95% CI 5.0–5.6) among men and
3.2% (95% CI 2.9–3.5) among women. Our results suggest
that almost 85% of the participants with markers of expo-
sure to HCV infection had not previously received a formal
diagnosis from medical personnel. Taking into account
the same routes of transmission, our participants were
asked about HIV testing, and no one reported HIV infec-
tion. Nevertheless, the HIV epidemic in the Arkhangelsk
region is scaling up; the incidence rate has risen from 10.6
to 27.7 per 100,000 during the last 5 years, and IDU is
considered to be responsible for at least 40% of all new
HIV cases in the region [42]. Many researchers support the
idea that Russia urgently needs to implement harm-
reduction programmes to prevent blood-borne infections
among people who practice IDU [43–45]. Data on needle/
syringe distribution is one of the core indicators of the
WHOmonitoring and evaluation framework for HCV elim-
ination in 2016–2021, but this indicator is not available in
most regions of Russia.
Sexual transmission of HCV is possible but occurs
seldom while the sexual transmission is a common
route of transmission of hepatitis B virus and HIV
[46,47]. Our study shows a low risk of sexual transmis-
sion of HCV. According to our data, the risk of being
HCV seropositive among participants with two or more
sexual partners during 6 months prior to the study was
the same as for those who knew someone with
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hepatitis C, although neither of these results were sig-
nificant. To our opinion, a relatively high rate of HIV
testing in the study sample (55.4% of men and 73.9% of
women) does not mean a selection of risk groups for
our study. According to Russian Sanitation Rules
3.1.5.2826–10 “Prevention of HIV infection” testing for
HIV infection is free of charge for all citizens. Moreover
all blood donors, pregnant women and their sexual
partners are tested for HIV during antenatal screening
while military personnel, hospitalized patients before
operations, people with Hepatitis B and C and other
groups during routine medical check-ups. About 22% of
the Russian population is tested for HIV every year [48].
Strengths and weaknesses of the study
Due to the cross-sectional design, a temporal relationship
between high-risk behaviour and HCV seropositivity could
not be established. Our sampling method cannot rule out
selection bias associated with recruitment via cell phone
owners. Even though the number of cell phones in
Arkhangelsk region was high in 2011 (1890/1000 popula-
tion, according to information from the Territorial Body of
the Federal State Statistics Service of the Arkhangelsk
region), generalisation of our study results should be
done with caution. Moreover, as we investigated the
adult population aged 18–39 years, we cannot generalise
our results to thewhole adult population of Arkhangelsk. In
addition, the study questionnaire contained sensitive ques-
tions, whichmay have caused social desirability bias due to
underreporting of high-risk behaviour [49]. However, more
people at risk for HCV infection may have chosen to attend
our study to avoid the stigmatisation they may have faced
at the ordinary clinics. Blood sampling, seen as unpleasant
by some, may have been a deterrent to participation [50].
The main strength of our study is its population-based
design, including both sexes and presentation of sex-
specific prevalence estimates. Other advantages of this
study are its sufficient sample size, the use of multivariable
statistics and adjustment for the most common potential
confounders. We chose to study adults aged 18–39 years
because that group is at highest risk for HCV infection [32].
To our knowledge, this study provides the most updated
information of HCV seroprevalence and associated factors
among young adults in an Arctic Russian urban setting in
the international peer-reviewed literature.
Conclusions
We observed a rather high seroprevalence of HCV among
the general population aged 18–39 years in Arkhangelsk.
Factors associated with HCV seropositivity were included
increasing age, IDU, and having received a blood
transfusion. HCV screening programmes in population
groups considered to be at risk for HCV infection should
be expanded, i.e. among persons practicing IDU, persons
acquiring tattoos or being subject to medical procedures/
blood transfusions abroad in places with unsafe hygienic
standard and testing routines. To reach the goal of the
World Health Organisation’s Global Health Sector Strategy
on Viral Hepatitis in reducing the incidence of andmortality
due to HCV infection in the next decade, regional preven-
tive programmes should includemeasures to reduce IDUas
well as harm-reduction and treatment programmes for
drug addicts.
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